{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:08:15Z","timestamp":1792789695490,"version":"4.5.0"},"reference-count":361,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017712","name":"Bureau of Science and Technology of Ganzhou Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017712","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218690","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:06:44Z","timestamp":1781968004000},"page":"218690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Immunotherapy resistance in triple-negative breast cancer: Mechanisms and emerging therapeutic strategies"],"prefix":"10.1016","volume":"658","author":[{"given":"Hui","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangnuer","family":"Nuerbieke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7647-864X","authenticated-orcid":false,"given":"Danni","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218690_bib1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1470-2045(25)00730-2","article-title":"Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the global burden of disease study 2023","volume":"27","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22381","article-title":"Prognostic markers in triple-negative breast cancer","volume":"109","author":"Rakha","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101149","article-title":"RGS5(+) lymphatic endothelial cells facilitate metastasis and acquired drug resistance of breast cancer through oxidative stress-sensing mechanism","volume":"77","author":"Qiu","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2026.218690_bib4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","article-title":"Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib5","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/2159-8290.CD-22-0200","article-title":"Proteogenomic markers of chemotherapy resistance and response in triple-negative breast cancer","volume":"12","author":"Anurag","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218690_bib6","article-title":"Association between biomarkers and clinical outcomes of pembrolizumab monotherapy in patients with metastatic triple-negative breast cancer: KEYNOTE-086 exploratory analysis","volume":"7","author":"Loi","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib8","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-18-3524","article-title":"Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer","volume":"25","author":"Xiao","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/path.5406","article-title":"The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice","volume":"250","author":"Gonzalez-Ericsson","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2026.218690_bib10","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s12282-021-01247-8","article-title":"Immune-related biomarkers in triple-negative breast cancer","volume":"28","author":"Zhang","year":"2021","journal-title":"Breast Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib11","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.7150\/jca.46301","article-title":"Identification of CTLA-4 associated with tumor microenvironment and competing interactions in triple negative breast cancer by co-expression network analysis","volume":"11","author":"Peng","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib12","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.2147\/OTT.S214211","article-title":"OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer","volume":"12","author":"Deng","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.canlet.2026.218690_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112692","article-title":"Combination of OX40 Co-stimulation, radiotherapy, and PD-1 inhibition in a syngeneic murine triple-negative breast cancer model","volume":"14","author":"Han","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218690_bib14","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1093\/oncolo\/oyab063","article-title":"Combining analysis of tumor-infiltrating lymphocytes (TIL) and PD-L1 refined the prognostication of breast cancer subtypes","volume":"27","author":"Ni","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2026.218690_bib15","article-title":"First cell therapy for solid tumours heads to the clinic: what it means for cancer treatment","author":"Reardon","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib16","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.21.02170","article-title":"Breast cancers are immunogenic: Immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes","volume":"40","author":"Zacharakis","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2033528","article-title":"Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure","volume":"11","author":"Wachsmann","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218690_bib18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2022.2054326","article-title":"CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress","volume":"31","author":"Corti","year":"2022","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.canlet.2026.218690_bib19","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.7150\/ijbs.70120","article-title":"CAR-T cell therapy for breast cancer: from basic research to clinical application","volume":"18","author":"Yang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.canlet.2026.218690_bib20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3389\/fimmu.2019.01149","article-title":"CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-022-06783-1","article-title":"EGFR as a potent CAR T target in triple negative breast cancer brain metastases","volume":"197","author":"Subham","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2026.218690_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jcyt.2022.10.012","article-title":"A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture","volume":"25","author":"O'Reilly","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.canlet.2026.218690_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583716","article-title":"Off-the-Shelf allogeneic T cell therapies for cancer: opportunities and challenges using naturally occurring \"Universal\" donor T cells","volume":"11","author":"Perez","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib24","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamaoncol.2024.3456","article-title":"Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: a systematic review and meta-analysis","volume":"10","author":"Villacampa","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib27","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218690_bib28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jama.2024.23560","article-title":"Camrelizumab vs placebo in combination with chemotherapy as neoadjuvant treatment in patients with early or locally advanced triple-negative breast cancer: the CamRelief randomized clinical trial","volume":"333","author":"Chen","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2026.218690_bib29","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib30","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218690_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib33","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib34","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","article-title":"Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib36","doi-asserted-by":"crossref","first-page":"394","DOI":"10.18632\/oncotarget.27877","article-title":"Tumor mutational burden as a predictor of immunotherapy response in breast cancer","volume":"12","author":"O'Meara","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218690_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103223","article-title":"Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials","volume":"159","author":"Tarantino","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2026.218690_bib38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib40","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib49","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/jnci\/djae129","article-title":"Neoadjuvant pembrolizumab plus chemotherapy\/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study","volume":"116","author":"Dent","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2026.218690_bib50","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib41","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib42","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101114","article-title":"Cancer plasticity in therapy resistance: mechanisms and novel strategies","volume":"76","author":"Niu","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2026.218690_bib44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.canlet.2026.218690_bib45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ccell.2024.11.008","article-title":"Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1","volume":"43","author":"Yang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib47","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","article-title":"Hypoxia induces HIF1\u03b1-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy","volume":"13","author":"Ma","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41422-023-00909-w","article-title":"ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer","volume":"34","author":"Ge","year":"2024","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2026.218690_bib51","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib52","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","article-title":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","volume":"35","author":"Dent","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib53","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/2159-8290.CD-23-0519","article-title":"NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple-negative breast cancer","volume":"14","author":"Taylor","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218690_bib54","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1016\/j.apsb.2024.04.009","article-title":"Enhancing immunotherapy efficacy against MHC-I deficient triple-negative breast cancer using LCL161-loaded macrophage membrane-decorated nanoparticles","volume":"14","author":"Zhang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2026.218690_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114532","article-title":"Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response","volume":"43","author":"Wofford","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218690_bib56","article-title":"CD8(+) T-cell exhaustion: impediment to triple-negative breast cancer (TNBC) immunotherapy","volume":"1879","author":"Feng","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2026.218690_bib57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/jcmm.17666","article-title":"Transforming growth factor-beta signalling in tumour resistance to the anti-PD-(L)1 therapy: updated","volume":"27","author":"Mortezaee","year":"2023","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib58","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib59","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/jcmm.17794","article-title":"Targeting the YAP\/TAZ mechanotransducers in solid tumour therapeutics","volume":"27","author":"Gargalionis","year":"2023","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib60","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib61","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.cell.2019.10.028","article-title":"B cells and T follicular helper cells mediate response to checkpoint inhibitors in high Mutation burden mouse models of breast cancer","volume":"179","author":"Hollern","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib62","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib63","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218690_bib64","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib65","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-19-0558","article-title":"Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer","volume":"25","author":"Liu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib66","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218690_bib67","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218690_bib68","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib69","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1158\/1078-0432.CCR-19-3507","article-title":"Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1\/L1 blockade in metastatic triple-negative breast cancer","volume":"26","author":"Barroso-Sousa","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.650491","article-title":"Tumor mutation burden and immune invasion characteristics in triple negative breast cancer: genome high-throughput data analysis","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib71","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10549-018-4753-7","article-title":"Mutant p53 in breast cancer: potential as a therapeutic target and biomarker","volume":"170","author":"Duffy","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2026.218690_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005068","article-title":"Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy","volume":"10","author":"Yang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib73","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-025-02505-5","article-title":"Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial)","volume":"25","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib74","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41586-024-08031-6","article-title":"AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution","volume":"635","author":"Schade","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf3066","article-title":"A protein interaction landscape of breast cancer","volume":"374","author":"Kim","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218690_bib76","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature11017","article-title":"The landscape of cancer genes and mutational processes in breast cancer","volume":"486","author":"Stephens","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib77","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"Nik-Zainal","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib78","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"486","author":"Shah","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib79","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","article-title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","volume":"30","author":"Pascual","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib80","article-title":"Elacestrant in metastatic breast cancer: current advancements and future perspectives","author":"Sahin","year":"2025","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.canlet.2026.218690_bib81","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218690_bib82","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218690_bib83","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-Deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218690_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14248854","article-title":"BRCA1 and 2 mutations and efficacy of pembrolizumab-based neoadjuvant chemotherapy in triple-negative breast cancer: a real-world multicenter analysis","volume":"14","author":"Fedele","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib85","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/jnci\/djab004","article-title":"Atezolizumab and nab-Paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study","volume":"113","author":"Emens","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2026.218690_bib86","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41419-025-07544-w","article-title":"Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application","volume":"16","author":"Pan","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218690_bib87","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","article-title":"CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours","volume":"618","author":"Kruse","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib88","doi-asserted-by":"crossref","first-page":"14467","DOI":"10.1073\/pnas.1508516112","article-title":"Engineering opportunities in cancer immunotherapy","volume":"112","author":"Jeanbart","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218690_bib89","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10585-023-10257-z","article-title":"Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade","volume":"41","author":"Wang","year":"2024","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.canlet.2026.218690_bib90","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1758834016658423","article-title":"Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond","volume":"8","author":"Migali","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib91","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s12026-019-09111-w","article-title":"Promotion on NLRC5 upregulating MHC-I expression by IFN-gamma in MHC-I-deficient breast cancer cells","volume":"67","author":"Zhao","year":"2019","journal-title":"Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218690_bib92","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/PAS.0000000000001653","article-title":"MHC class I loss in triple-negative breast cancer: a potential barrier to PD-1\/PD-L1 checkpoint inhibitors","volume":"45","author":"Dusenbery","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.canlet.2026.218690_bib93","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","article-title":"Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer","volume":"42","author":"Shiao","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib94","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1038\/s41467-022-31238-y","article-title":"Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer","volume":"13","author":"Lee","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib95","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140837","article-title":"MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation","volume":"131","author":"Fang","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218690_bib96","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41419-025-07944-y","article-title":"Inhibition of ATM enhances the immunogenicity of triple-negative breast cancer by promoting MHC-I expression","volume":"16","author":"Li","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218690_bib97","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1158\/1078-0432.CCR-17-2483","article-title":"The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression","volume":"24","author":"Huang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib99","article-title":"Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling","volume":"12","author":"Park","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218690_bib100","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1158\/1078-0432.CCR-21-0607","article-title":"Tumor-specific major Histocompatibility-II expression predicts benefit to Anti-PD-1\/L1 therapy in patients with HER2-Negative primary breast cancer","volume":"27","author":"Gonzalez-Ericsson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib101","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41556-025-01627-8","article-title":"ADSL-generated fumarate binds and inhibits STING to promote tumour immune evasion","volume":"27","author":"Duan","year":"2025","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218690_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2025.07.013","article-title":"Inhibition of tumor cell macropinocytosis driver DHODH reverses immunosuppression and overcomes anti-PD1 resistance","author":"Wang","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218690_bib103","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s43018-022-00339-4","article-title":"LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer","volume":"3","author":"Perez-Nunez","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib104","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41392-025-02472-9","article-title":"Family with sequence similarity 114 member A1 orchestrates immune evasion in triple-negative breast cancer","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218690_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040663","article-title":"Recent advancements in the mechanisms underlying resistance to PD-1\/PD-L1 blockade immunotherapy","volume":"13","author":"Yuan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218690_bib106","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.62347\/ANXS3815","article-title":"Cardamonin anticancer effects through the modulation of the tumor immune microenvironment in triple-negative breast cancer cells","volume":"14","author":"Mendonca","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib107","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1158\/0008-5472.CAN-17-1636","article-title":"MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer","volume":"78","author":"Maeda","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib108","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13578-023-01137-w","article-title":"Niclosamide improves cancer immunotherapy by modulating RNA-binding protein HuR-mediated PD-L1 signaling","volume":"13","author":"Zhang","year":"2023","journal-title":"Cell Biosci."},{"key":"10.1016\/j.canlet.2026.218690_bib109","first-page":"75","article-title":"Immunotherapy for triple-negative breast cancer: a molecular insight into the microenvironment, treatment, and resistance","volume":"1","author":"Bai","year":"2021","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.canlet.2026.218690_bib110","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1038\/s41467-023-37727-y","article-title":"Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer","volume":"14","author":"Palakurthi","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib111","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib112","first-page":"123","article-title":"De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients","volume":"12","author":"Ou-Yang","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib113","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41588-025-02077-6","article-title":"Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma","volume":"57","author":"Liang","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2026.218690_bib114","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41419-023-05609-2","article-title":"LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1-TINCR-USP20-PD-L1 axis","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218690_bib115","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1097\/JS9.0000000000002164","article-title":"Loss of RPN1 promotes antitumor immunity via PD-L1 checkpoint blockade in triple-negative breast cancer - experimental studies","volume":"111","author":"Wang","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.canlet.2026.218690_bib116","first-page":"13","article-title":"Epithelial to mesenchymal transition regulates surface PD-L1 via CMTM6 and CMTM7 induction in breast cancer","author":"Xiao","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218690_bib117","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41586-023-06367-z","article-title":"Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer","volume":"620","author":"Cassier","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib118","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib119","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ccell.2025.02.014","article-title":"Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy","volume":"43","author":"Song","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40164-024-00546-y","article-title":"Overexpression of ESYT3 improves radioimmune responses through activating cGAS-STING pathway in lung adenocarcinoma","volume":"13","author":"Luo","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib121","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1097\/CM9.0000000000002329","article-title":"Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer","volume":"135","author":"Li","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.canlet.2026.218690_bib122","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2326-6066.CIR-21-0826","article-title":"Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer","volume":"10","author":"Lee","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218690_bib123","first-page":"13","article-title":"Thrombospondin-1 silencing improves lymphocyte infiltration in tumors and response to Anti-PD-1 in triple-negative breast cancer","author":"Marcheteau","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218690_bib124","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.7150\/thno.74989","article-title":"UBR5 promotes tumor immune evasion through enhancing IFN-gamma-induced PDL1 transcription in triple negative breast cancer","volume":"12","author":"Wu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218690_bib125","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1021\/acs.molpharmaceut.2c00701","article-title":"Camptothesome potentiates PD-L1 immune checkpoint blockade for improved metastatic triple-negative breast cancer immunochemotherapy","volume":"19","author":"Wang","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.canlet.2026.218690_bib126","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218690_bib127","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2174\/0115748928305105240417101251","article-title":"The emerging role of ADAM 12 regulates epithelial-mesenchymal transition by activating the Wnt\/\u03b2-catenin signaling pathway in colorectal cancer","volume":"20","author":"Huang","year":"2025","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.canlet.2026.218690_bib128","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191115","article-title":"\u03b2-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion","volume":"217","author":"Du","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib129","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12943-020-01276-5","article-title":"Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities","volume":"19","author":"Xu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib130","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2174\/0115748928267931231120065335","article-title":"Targeting the key signaling pathways in breast cancer: from molecular mechanism to therapeutic interventions","volume":"20","author":"Singh","year":"2025","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.canlet.2026.218690_bib131","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1186\/s12885-020-07500-1","article-title":"RX-5902, a novel beta-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast cancer","volume":"20","author":"Tentler","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib132","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1535-7163.MCT-18-1334","article-title":"First-in-Class Phosphorylated-p68 inhibitor RX-5902 inhibits beta-catenin signaling and demonstrates antitumor activity in triple-negative breast cancer","volume":"18","author":"Capasso","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218690_bib133","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202203019","article-title":"Drug self-delivery nanocubes enhance O(2) -Economized photodynamic-immunotherapy of triple-negative breast cancer by downregulating Wnt\/beta-catenin signaling","volume":"12","author":"Feng","year":"2023","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.canlet.2026.218690_bib134","doi-asserted-by":"crossref","first-page":"38333","DOI":"10.1021\/acsami.5c04799","article-title":"A multimodal nanoplatform integrating photodynamic therapy and Wnt\/beta-Catenin inhibition reprograms the tumor microenvironment to potentiate immune checkpoint therapy in triple-negative breast cancer","volume":"17","author":"Zeng","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.canlet.2026.218690_bib135","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218690_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217865","article-title":"The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): emerging therapeutic opportunities","volume":"628","author":"Sabit","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218690_bib137","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/0115748928258157231128103337","article-title":"Identification of breast cancer immune-related prognostic characteristics in tumor microenvironment","volume":"20","author":"Tang","year":"2025","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.canlet.2026.218690_bib138","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-Infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2026.218690_bib139","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib140","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib141","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1158\/1078-0432.CCR-19-2179","article-title":"Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade","volume":"26","author":"Li","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib142","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1263537","article-title":"Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib143","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2174\/0115748928350267250105153944","article-title":"A three-agent regimen for triple negative breast cancer treatment","volume":"20","author":"Wang","year":"2025","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.canlet.2026.218690_bib144","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s41590-025-02172-0","article-title":"PD-1 receptor deficiency enhances CD30(+) T(reg) cell function in melanoma","volume":"26","author":"Lim","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib145","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.canlet.2026.218690_bib146","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13058-025-02003-y","article-title":"Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy","volume":"27","author":"Wang","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib147","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","article-title":"Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity","volume":"187","author":"Cillo","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib148","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib clinical trial of sabatolimab, an Anti-TIM-3 antibody, alone and in combination with spartalizumab, an Anti-PD-1 antibody, in advanced solid tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib149","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12964-025-02638-6","article-title":"Targeting T cell exhaustion in colorectal cancer: emerging roles of LAG-3, TIM-3, and TIGIT signaling in overcoming immunotherapy resistance","volume":"24","author":"Zamani","year":"2026","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.canlet.2026.218690_bib150","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.imbio.2016.04.005","article-title":"Tim-3 identifies exhausted follicular helper T cells in breast cancer patients","volume":"221","author":"Zhu","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.canlet.2026.218690_bib151","article-title":"Breast cancer cells and PD-1\/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoints in CD4(+) T cells","volume":"7","author":"Saleh","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.canlet.2026.218690_bib152","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.21037\/atm-21-3848","article-title":"The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer","volume":"9","author":"Miao","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib153","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s12885-021-08054-6","article-title":"TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer","volume":"21","author":"Cabioglu","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib154","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s10549-021-06128-4","article-title":"Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients","volume":"186","author":"Liu","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2026.218690_bib155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-021-01437-4","article-title":"Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study","volume":"23","author":"Sarradin","year":"2021","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib156","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3892\/ol.2022.13318","article-title":"Prognostic significance of the expression levels of T-cell immunoglobulin mucin-3 and its ligand galectin-9 for relapse-free survival in triple-negative breast cancer","volume":"23","author":"Yoshikawa","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2026.218690_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9101383","article-title":"Association of galectin 9 expression with immune cell infiltration, programmed cell death Ligand-1 expression, and patient's clinical outcome in triple-negative breast cancer","volume":"9","author":"Ju","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.canlet.2026.218690_bib158","doi-asserted-by":"crossref","first-page":"142","DOI":"10.55730\/1300-0144.5567","article-title":"LAG-3 expression in tumor microenvironment of triple-negative breast cancer","volume":"53","author":"Tahtaci","year":"2023","journal-title":"Turk. J. Med. Sci."},{"key":"10.1016\/j.canlet.2026.218690_bib159","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102656","article-title":"Prognostic impact of LAG-3 mRNA expression in early breast cancer","volume":"10","author":"Heimes","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.canlet.2026.218690_bib160","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/PAI.0000000000000954","article-title":"Prognostic and clinicopathologic associations of LAG-3 expression in triple-negative breast cancer","volume":"30","author":"Stovgaard","year":"2022","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.canlet.2026.218690_bib161","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41586-025-09000-3","article-title":"STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity","volume":"643","author":"Zhou","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib162","article-title":"Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib163","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/imt.13.169","article-title":"Dendritic cell-based vaccines: clinical applications in breast cancer","volume":"6","author":"Gelao","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.canlet.2026.218690_bib164","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1158\/1078-0432.CCR-21-0343","article-title":"Characteristics and spatially defined immune (micro)landscapes of early-stage PD-L1-positive triple-negative breast cancer","volume":"27","author":"Carter","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib165","article-title":"Tumor-derived CDC37 inhibits antigen cross-presentation in dendritic cells and impairs anti-tumor immunity in breast cancer","volume":"13","author":"Wang","year":"2026","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218690_bib166","article-title":"PH20-modified exosomes loaded curcumin inhibit desmoplastic breast cancer by breaking extracellular matrix barrier and normalizing cancer-associated fibroblasts","volume":"35","author":"Xue","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.canlet.2026.218690_bib167","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib168","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1455211","article-title":"Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer","volume":"15","author":"Singh","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.108537","article-title":"Proteomic, single-cell and bulk transcriptomic analysis of plasma and tumor tissues unveil core proteins in response to anti-PD-L1 immunotherapy in triple negative breast cancer","volume":"176","author":"Li","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib170","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib171","article-title":"Cancer-associated fibroblasts-derived lncRNA signature as a putative biomarker in breast cancer","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib172","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13058-023-01684-7","article-title":"Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3\/AKT pathways","volume":"25","author":"Chuangchot","year":"2023","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib173","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.7150\/thno.68972","article-title":"FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts","volume":"12","author":"Wu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218690_bib174","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semcancer.2019.07.017","article-title":"Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression","volume":"65","author":"Saleh","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2026.218690_bib175","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1158\/0008-5472.CAN-22-1427","article-title":"Lipid-Associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer","volume":"82","author":"Timperi","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib176","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1754311","article-title":"Molecular remodeling of cancer-associated fibroblasts in breast cancer patients receiving anti-PD-1 immunotherapy","volume":"16","author":"Do","year":"2026","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107724","article-title":"NAALAD2 mutations disrupt the fate of photoreceptor cells and retinal pigment epithelial cells during early retinal development","volume":"215","author":"Qian","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2026.218690_bib178","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s40001-024-02179-7","article-title":"Analysis of immune cell activation in patients with diabetes foot ulcer from the perspective of single cell","volume":"29","author":"Vu","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.canlet.2026.218690_bib179","article-title":"Single-cell landscape of bronchoalveolar lavage fluid identifies specific neutrophils during septic immunosuppression","volume":"12","author":"Shen","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218690_bib180","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019104063","article-title":"Stromal cell diversity associated with immune evasion in human triple-negative breast cancer","volume":"39","author":"Wu","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2026.218690_bib181","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib182","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1038\/s41467-023-39762-1","article-title":"Cancer-associated fibroblast classification in single-cell and spatial proteomics data","volume":"14","author":"Cords","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib183","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41467-025-57465-7","article-title":"Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response","volume":"16","author":"Song","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217475","article-title":"FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity","volume":"612","author":"Wei","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218690_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2026.03.011","article-title":"Co-delivery nanoparticle targeting CAF for simultaneous activating T cell plus NKT cell attack in solid tumor","author":"Xiang","year":"2026","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.canlet.2026.218690_bib186","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/s41388-025-03359-3","article-title":"Fibroblast activation protein (FAP)(+) cancer-associated fibroblasts induce macrophage M2-like polarization via the fibronectin 1-Integrin \u03b15\u03b21 axis in breast cancer","volume":"44","author":"Chen","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218690_bib187","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218690_bib188","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1158\/1078-0432.CCR-20-3715","article-title":"Inhibition of hedgehog signaling alters fibroblast composition in pancreatic cancer","volume":"27","author":"Steele","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib189","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.620773","article-title":"Macrophages and extracellular matrix in breast cancer: partners in crime or protective allies?","volume":"11","author":"Deligne","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib190","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ctrv.2018.08.010","article-title":"Tumor-associated macrophages in breast cancer: innocent bystander or important player?","volume":"70","author":"Qiu","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2026.218690_bib191","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41419-020-02926-8","article-title":"M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2","volume":"11","author":"Dong","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218690_bib192","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217772","article-title":"Macrophage polarization in cancer and beyond: from inflammatory signaling pathways to potential therapeutic strategies","volume":"625","author":"Bai","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218690_bib193","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.imbio.2017.11.001","article-title":"Macrophages: their role, activation and polarization in pulmonary diseases","volume":"223","author":"Arora","year":"2018","journal-title":"Immunobiology"},{"key":"10.1016\/j.canlet.2026.218690_bib194","doi-asserted-by":"crossref","first-page":"13","DOI":"10.12703\/P6-13","article-title":"The M1 and M2 paradigm of macrophage activation: time for reassessment","volume":"6","author":"Martinez","year":"2014","journal-title":"F1000Prime Rep."},{"key":"10.1016\/j.canlet.2026.218690_bib195","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib196","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib197","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccr.2014.03.021","article-title":"A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis","volume":"25","author":"Su","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib198","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13058-015-0621-0","article-title":"Human breast cancer cells educate macrophages toward the M2 activation status","volume":"17","author":"Sousa","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib199","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.4049\/jimmunol.1402603","article-title":"Intratumoral delivery of IL-21 overcomes Anti-Her2\/Neu resistance through shifting tumor-associated macrophages from M2 to M1 phenotype","volume":"194","author":"Xu","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib200","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","article-title":"Macrophages and therapeutic resistance in cancer","volume":"27","author":"Ruffell","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib201","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","article-title":"Tumor-associated macrophages: an accomplice in solid tumor progression","volume":"26","author":"Chen","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.canlet.2026.218690_bib202","doi-asserted-by":"crossref","first-page":"8514","DOI":"10.1038\/s41467-024-52553-6","article-title":"Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy","volume":"15","author":"Zheng","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib203","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12943-019-0988-0","article-title":"MCT-1\/miR-34a\/IL-6\/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer","volume":"18","author":"Weng","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib204","article-title":"Tumor-associated macrophage subsets: shaping polarization and targeting","volume":"24","author":"Zhang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218690_bib205","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40364-024-00719-1","article-title":"MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2\/MORF4L2\/H4K12Ac\/CSF1 axis in triple-negative breast cancer","volume":"13","author":"Sui","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.canlet.2026.218690_bib206","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s43018-025-00930-5","article-title":"Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors","volume":"6","author":"Tao","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib207","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113740","article-title":"PPAB001, a novel bispecific antibody against CD47 and CD24, enhances anti-PD-L1 efficacy in triple-negative breast cancer via reprogramming tumor-associated macrophages towards M1 phenotype","volume":"144","author":"Yang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2026.218690_bib208","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","article-title":"Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer","volume":"12","author":"Hammerl","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib209","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4168\/aair.2020.12.6.1012","article-title":"Chitinase 3-Like 1 contributes to food allergy via M2 macrophage polarization","volume":"12","author":"Kim","year":"2020","journal-title":"Allergy Asthma Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218690_bib210","article-title":"CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167581","article-title":"Depression decreases immunity and PD-L1 inhibitor efficacy via the hypothalamic-pituitary-adrenal (HPA) axis in triple-negative breast cancer","volume":"1871","author":"Yu","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.canlet.2026.218690_bib212","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010046","article-title":"Current strategies to target tumor-associated-macrophages to improve anti-tumor immune responses","volume":"9","author":"Anfray","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218690_bib213","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib214","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2063225","article-title":"Tumor-associated macrophages promote intratumoral conversion of conventional CD4(+) T cells into regulatory T cells via PD-1 signalling","volume":"11","author":"Kos","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218690_bib215","article-title":"Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218690_bib216","first-page":"2878","article-title":"Blockade of CCL2 expression overcomes intrinsic PD-1\/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer","volume":"10","author":"Choi","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib217","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.canlet.2026.218690_bib218","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3604","article-title":"In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib219","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coi.2014.12.009","article-title":"Suppression of antigen presentation by IL-10","volume":"34","author":"Mittal","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib220","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.cmet.2025.08.009","article-title":"HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer","volume":"37","author":"Xiao","year":"2025","journal-title":"Cell Metab."},{"key":"10.1016\/j.canlet.2026.218690_bib221","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009877","article-title":"AKAP12 positive fibroblast determines immunosuppressive contexture and immunotherapy response in patients with TNBC by promoting macrophage M2 polarization","volume":"12","author":"Liu","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib222","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.182621","article-title":"CREB-binding protein\/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer","volume":"9","author":"Yuan","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218690_bib223","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41556-019-0373-7","article-title":"Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms","volume":"21","author":"Kim","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218690_bib224","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1158\/2159-8290.CD-24-0415","article-title":"Activated T cells break tumor immunosuppression by macrophage reeducation","volume":"15","author":"Trotta","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218690_bib225","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","article-title":"Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216805","article-title":"The mast cell-T lymphocyte axis impacts cancer: friend or foe?","volume":"588","author":"Kannen","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218690_bib227","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/s41591-025-03776-7","article-title":"Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial","volume":"31","author":"Wu","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib228","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1158\/0008-5472.CAN-21-3714","article-title":"Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer","volume":"82","author":"Singh","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib229","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114920","article-title":"CD84 as a therapeutic target for breaking immune tolerance in triple-negative breast cancer","volume":"43","author":"Rabani","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218690_bib230","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","article-title":"B cells, plasma cells and antibody repertoires in the tumour microenvironment","volume":"20","author":"Sharonov","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib231","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41523-021-00291-z","article-title":"Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome","volume":"7","author":"Wortman","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib232","article-title":"The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1(+) regulator B cells mediates immunosuppression in triple-negative breast cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib233","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib234","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1172\/JCI99673","article-title":"\u0394Np63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer","volume":"128","author":"Kumar","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218690_bib235","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s42003-021-02375-9","article-title":"Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells","volume":"4","author":"Vito","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.canlet.2026.218690_bib236","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg3736","article-title":"Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy","volume":"9","author":"Sarkar","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218690_bib237","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.590794","article-title":"Obesity-Associated myeloid-derived suppressor cells promote apoptosis of tumor-infiltrating CD8 T cells and immunotherapy resistance in breast cancer","volume":"11","author":"Gibson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib238","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1413520","article-title":"A novel MDSC-induced PD-1(-)PD-L1(+) B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties","volume":"7","author":"Shen","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218690_bib239","first-page":"915","volume":"vol. 8","author":"Wang","year":"2025"},{"key":"10.1016\/j.canlet.2026.218690_bib240","article-title":"KAT6A acetylation of SMAD3 regulates myeloid-derived suppressor cell recruitment, metastasis, and immunotherapy in triple-negative breast cancer","volume":"8","author":"Yu","year":"2021","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218690_bib241","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","article-title":"Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours","volume":"637","author":"Melero","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib242","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1038\/s41467-023-39817-3","article-title":"Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment","volume":"14","author":"Haake","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib243","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41586-024-08510-w","article-title":"IL-27 elicits a cytotoxic CD8(+) T cell program to enforce tumour control","volume":"639","author":"Breart","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib244","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41586-021-03614-z","article-title":"Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy","volume":"594","author":"Correia","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib245","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41590-022-01213-2","article-title":"Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies","volume":"23","author":"Kansler","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib246","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.05.011","article-title":"Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling","author":"Nikolic","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib247","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1016\/j.immuni.2023.11.002","article-title":"The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer","volume":"56","author":"Taifour","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218690_bib248","doi-asserted-by":"crossref","DOI":"10.1172\/JCI137750","article-title":"CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses","volume":"131","author":"Ma","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218690_bib249","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj7808","article-title":"Interferon-induced senescent CD8(+) T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer","volume":"17","author":"Fu","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib250","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41467-025-57603-1","article-title":"Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice","volume":"16","author":"Wen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib251","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119769","article-title":"Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model","volume":"235","author":"Xu","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2026.218690_bib252","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","article-title":"Hypoxia induces HIF1alpha-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy","volume":"13","author":"Ma","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib253","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib254","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jconrel.2025.01.042","article-title":"Chitosan\/gamma-PGA nanoparticles and IFN-gamma immunotherapy: a dual approach for triple-negative breast cancer treatment","volume":"379","author":"Castro","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2026.218690_bib255","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218690_bib256","doi-asserted-by":"crossref","DOI":"10.2174\/0115748928416410251128094143","article-title":"Histone deacetylases as epigenetic regulators of EMT in hypoxia-driven tumor metastasis: mechanistic insights and therapeutic implications","author":"Bao","year":"2026","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.canlet.2026.218690_bib257","doi-asserted-by":"crossref","DOI":"10.2174\/0115748928413005251129104036","article-title":"Lactylation plays a novel role in the tumor microenvironment and its prognostic implications for breast cancer","author":"Gao","year":"2026","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.canlet.2026.218690_bib258","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-026-02568-y","article-title":"piR-1170 drives brain metastasis and immune evasion via WTAP-mediated m6A methylation reprogramming in triple-negative breast cancer","volume":"25","author":"Luo","year":"2026","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib259","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cytogfr.2023.08.010","article-title":"Exosome-mediated metabolic reprogramming: implications in esophageal carcinoma progression and tumor microenvironment remodeling","volume":"73","author":"Xi","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.canlet.2026.218690_bib260","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib261","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.trecan.2019.05.010","article-title":"Integrative approaches to cancer immunotherapy","volume":"5","author":"Szeto","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib262","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13046-024-03042-7","article-title":"Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication","volume":"43","author":"Chen","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218690_bib263","doi-asserted-by":"crossref","DOI":"10.1002\/cai2.124","article-title":"A lactate-responsive gene signature predicts the prognosis and immunotherapeutic response of patients with triple-negative breast cancer","volume":"3","author":"Feng","year":"2024","journal-title":"Cancer Innov"},{"key":"10.1016\/j.canlet.2026.218690_bib264","first-page":"13","article-title":"Emerging role of extracellular pH in tumor microenvironment as a therapeutic target for cancer immunotherapy","author":"Rahman","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218690_bib265","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15204931","article-title":"Immunotherapy enhancement by targeting extracellular tumor pH in triple-negative breast cancer mouse model","volume":"15","author":"Rahman","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218690_bib266","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.10.012","article-title":"DHDH-mediated D-xylose metabolism induces immune evasion in triple-negative breast cancer","volume":"6","author":"Wu","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.canlet.2026.218690_bib267","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1365-2567.2002.01526.x","article-title":"Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division","volume":"107","author":"Lee","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2026.218690_bib268","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.immuni.2025.03.002","article-title":"Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer","volume":"58","author":"Yu","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218690_bib269","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218278","article-title":"FIG4 downregulation-arrested autophagy-lysosomal degradation of IL-18 drives lipid-associated macrophage polarization and immunotherapy resistance in triple-negative breast cancer","volume":"641","author":"Xia","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218690_bib270","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41589-022-01024-4","article-title":"PRMT inhibition induces a viral mimicry response in triple-negative breast cancer","volume":"18","author":"Wu","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2026.218690_bib271","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107367","article-title":"Development of a DNA aptamer targeting IDO1 with anti-tumor effects","volume":"26","author":"Zhu","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.canlet.2026.218690_bib272","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41586-023-05968-y","article-title":"The neuroscience of cancer","volume":"618","author":"Mancusi","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib273","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ccell.2023.02.012","article-title":"Cancer hallmarks intersect with neuroscience in the tumor microenvironment","volume":"41","author":"Hanahan","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib274","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41568-025-00831-w","article-title":"Neuro-immune cross-talk in cancer","volume":"25","author":"Amit","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib275","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-09370-8","article-title":"Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy","author":"Baruch","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib276","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101212","article-title":"Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer","volume":"79","author":"Li","year":"2025","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2026.218690_bib277","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41586-025-09176-8","article-title":"Nerve-to-cancer transfer of mitochondria during cancer metastasis","volume":"644","author":"Hoover","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib278","article-title":"AKT1 phosphorylates FDX1 to promote cuproptosis resistance in triple-negative breast cancer","volume":"12","author":"Sun","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218690_bib279","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/s41589-025-01887-3","article-title":"PSAT1 impairs ferroptosis and reduces immunotherapy efficacy via GPX4 hydroxylation","volume":"21","author":"Zheng","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2026.218690_bib280","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006890","article-title":"PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis","volume":"11","author":"Wang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib281","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.semcancer.2022.03.009","article-title":"Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: perspectives for immunotherapy of SCLC","volume":"86","author":"Niu","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2026.218690_bib282","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2756611","article-title":"Definition of a novel cuproptosis-relevant lncRNA signature for uncovering distinct survival, genomic alterations, and treatment implications in lung adenocarcinoma","volume":"2022","author":"Wang","year":"2022","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218690_bib283","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101224","article-title":"DTX2 attenuates Lenvatinib-induced ferroptosis by suppressing docosahexaenoic acid biosynthesis through HSD17B4-dependent peroxisomal \u03b2-oxidation in hepatocellular carcinoma","volume":"81","author":"Zhang","year":"2025","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2026.218690_bib284","article-title":"Ubiquitination-related gene UBTD1 mediates poor prognosis of colorectal cancer and affects colorectal cancer cell proliferation and ferroptosis","author":"Jin","year":"2025","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.canlet.2026.218690_bib285","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12943-024-02130-8","article-title":"Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib286","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1021\/acsnano.2c10893","article-title":"Oxygen self-generating nanoreactor mediated ferroptosis activation and immunotherapy in triple-negative breast cancer","volume":"17","author":"Li","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2026.218690_bib287","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","article-title":"Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications","volume":"185","author":"Stockwell","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218690_bib288","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tips.2023.06.005","article-title":"Ferroptosis of immune cells in the tumor microenvironment","volume":"44","author":"Kim","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.canlet.2026.218690_bib289","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1007\/s11010-025-05305-z","article-title":"Ferroptosis in TNBC: interplay with tumor-infiltrating immune cells and therapeutic implications","volume":"480","author":"Hu","year":"2025","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.canlet.2026.218690_bib290","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bbrc.2019.01.090","article-title":"The release and activity of HMGB1 in ferroptosis","volume":"510","author":"Wen","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib291","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1038\/s41467-020-17380-5","article-title":"Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy","volume":"11","author":"Yu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib292","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1080\/15548627.2020.1714209","article-title":"Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein","volume":"16","author":"Dai","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2026.218690_bib293","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.15060","article-title":"Ferroptosis-dependent breast cancer cell-derived exosomes inhibit migration and invasion of breast cancer cells by suppressing M2 macrophage polarization","volume":"11","author":"Yi","year":"2023","journal-title":"PeerJ"},{"key":"10.1016\/j.canlet.2026.218690_bib294","article-title":"Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy","volume":"16","author":"Jiang","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.canlet.2026.218690_bib295","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218690_bib296","article-title":"Ferroptosis and its interaction with tumor immune microenvironment in liver cancer","volume":"1878","author":"Huang","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2026.218690_bib297","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-025-00864-1","article-title":"Decoding ferroptosis for cancer therapy","author":"Wahida","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib298","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1038\/s41467-022-31218-2","article-title":"Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity","volume":"13","author":"Wiernicki","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib299","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101018","article-title":"Cuproptosis: a novel therapeutic target for overcoming cancer drug resistance","volume":"72","author":"Wang","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2026.218690_bib300","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218192","article-title":"Copper orchestrates triple-negative breast cancer progression via the STEAP3-dependent CDK16-JAK1 activation","volume":"639","author":"Duan","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218690_bib301","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978909","article-title":"Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer","volume":"13","author":"Song","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218690_bib302","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123538","article-title":"Lactate metabolism regulating nanosystem synergizes cuproptosis and ferroptosis to enhance cancer immunotherapy","volume":"325","author":"Zhi","year":"2026","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2026.218690_bib303","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12951-025-03139-x","article-title":"Platycodon grandiflorum-derived extracellular vesicles suppress triple-negative breast cancer growth by reversing the immunosuppressive tumor microenvironment and modulating the gut microbiota","volume":"23","author":"Yang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.canlet.2026.218690_bib304","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cmet.2022.02.010","article-title":"The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer","volume":"34","author":"Wang","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.canlet.2026.218690_bib305","article-title":"Gut microbiome influences incidence and outcomes of breast cancer by regulating levels and activity of steroid hormones in women","volume":"6","author":"Chapadgaonkar","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.canlet.2026.218690_bib306","article-title":"Mendelian randomization analysis revealed a gut microbiota-mammary axis in breast cancer","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.canlet.2026.218690_bib307","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.semcancer.2025.10.006","article-title":"Microbial modulation as a game changer: boosting immunotherapy efficacy in breast cancer","volume":"117","author":"Xia","year":"2025","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2026.218690_bib308","doi-asserted-by":"crossref","first-page":"26296","DOI":"10.1021\/jacs.3c09472","article-title":"Transforming intratumor bacteria into immunopotentiators to reverse cold tumors for enhanced immuno-chemodynamic therapy of triple-negative breast cancer","volume":"145","author":"Liu","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.canlet.2026.218690_bib309","article-title":"A high-fat diet promotes cancer progression by inducing gut microbiota-mediated leucine production and PMN-MDSC differentiation","volume":"121","author":"Chen","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218690_bib310","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102198","article-title":"Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis","volume":"8","author":"Rizzo","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.canlet.2026.218690_bib311","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218690_bib312","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.7150\/ijbs.118427","article-title":"Synergistic effects of radiotherapy and PD-1 blockade in a human-mimetic BRCAness model of triple-negative breast cancer","volume":"21","author":"Cho","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.canlet.2026.218690_bib313","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12929-025-01173-3","article-title":"CDK4\/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer","volume":"32","author":"Yang","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.canlet.2026.218690_bib314","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102924","article-title":"Post-progression treatment options after CDK4\/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"135","author":"Sahin","year":"2025","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2026.218690_bib315","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104740","article-title":"PD-1\/PD-L1 inhibitors combined with anti-angiogenic drugs for advanced triple-negative breast cancer: synergistic mechanisms and research progress","volume":"211","author":"Xu","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2026.218690_bib316","article-title":"Neoadjuvant anlotinib\/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): phase 2 trial","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib317","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007126","article-title":"Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)","volume":"11","author":"Masuda","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib318","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2026.218690_bib319","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000696","article-title":"Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial","volume":"8","author":"Liu","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib320","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008037","article-title":"Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors","volume":"12","author":"Frentzas","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib321","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-020-01295-y","article-title":"Atezolizumab (in combination with Nab-Paclitaxel): a review in advanced triple-negative breast cancer","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2026.218690_bib322","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-Positive\/Human epidermal growth factor receptor 2-Negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib323","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1362641","article-title":"Sacituzumab govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis","volume":"14","author":"Caputo","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib324","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/tbcr-25-32","article-title":"Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04","volume":"6","author":"Bian","year":"2025","journal-title":"Transl Breast Cancer Res"},{"key":"10.1016\/j.canlet.2026.218690_bib325","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28385","article-title":"Datopotamab deruxtecan: a novel antibody drug conjugate for triple-negative breast cancer","volume":"10","author":"Schipilliti","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.canlet.2026.218690_bib326","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/13543784.2022.2042252","article-title":"Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.canlet.2026.218690_bib327","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251327992","article-title":"TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","volume":"17","author":"Schmid","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib328","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib329","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib330","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl3649","article-title":"Albumin nanoparticle containing a PI3Kgamma inhibitor and paclitaxel in combination with alpha-PD1 induces tumor remission of breast cancer in mice","volume":"14","author":"Song","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib331","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007336","article-title":"Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer","volume":"11","author":"Brito Baleeiro","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib332","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.canlet.2013.03.010","article-title":"Blockade of PD-1\/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice","volume":"336","author":"Ge","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218690_bib333","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000465","article-title":"Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8(+) T-cell functionality","volume":"8","author":"Niavarani","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib334","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1158\/1535-7163.MCT-23-0303","article-title":"Combination therapies to improve the efficacy of immunotherapy in triple-negative breast cancer","volume":"22","author":"Aleckovic","year":"2023","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218690_bib335","article-title":"DCC-2036 induces repolarization of TAMs to M1 type and enhances CD8(+) T cell immunity in TNBC","author":"Liang","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218690_bib336","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1186\/s12967-025-07105-x","article-title":"A novel anti-PD-L1\/IL-8 bispecific antibody BP2402 enhances antitumor immunity and modulates inflammatory signaling in triple-negative breast cancer mice model","volume":"23","author":"Song","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib337","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","article-title":"Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy","volume":"35","author":"Yang","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.canlet.2026.218690_bib338","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26199686","article-title":"Metabolic regulation of ferroptosis in breast cancer","volume":"26","author":"Glibetic","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218690_bib339","article-title":"Nanotechnology-enhanced immunotherapy for metastatic cancer","volume":"2","author":"Zhang","year":"2021","journal-title":"Innovation"},{"key":"10.1016\/j.canlet.2026.218690_bib340","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101098","article-title":"Application of biomimetic nanovaccines in cancer immunotherapy: a useful strategy to help combat immunotherapy resistance","volume":"75","author":"Xu","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2026.218690_bib361","article-title":"Cancer immunotherapy based on the bidirectional reprogramming of the tumor microenvironment by a \"Brakes Off\/Step on the Accelerator\" core-shell manganese Phosphate\/siPD-L1 modulator","volume":"5","author":"Xia","year":"2025","journal-title":"Exploration (Beijing)"},{"key":"10.1016\/j.canlet.2026.218690_bib341","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123679","article-title":"Precision targeted cancer-associated fibroblast nano-regulator enhanced chemo-immunotherapy for triple-negative breast cancer","volume":"326","author":"Xian","year":"2026","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2026.218690_bib342","article-title":"Nanoparticles synergize ferroptosis and cuproptosis to potentiate cancer immunotherapy","volume":"11","author":"Li","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218690_bib343","first-page":"483","article-title":"Ca & Mn dual-ion hybrid nanostimulator boosting anti-tumor immunity via ferroptosis and innate immunity awakening","volume":"33","author":"Deng","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.canlet.2026.218690_bib344","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202404580","article-title":"A bimetallic nanomodulator to reverse immunosuppression via sonodynamic-ferroptosis and lactate metabolism modulation","volume":"20","author":"Deng","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.canlet.2026.218690_bib346","article-title":"Thermosensitive hydrogel-mediated chemo-photothermal combined immunotherapy for triple-negative breast cancer","author":"Luo","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.canlet.2026.218690_bib347","doi-asserted-by":"crossref","first-page":"36323","DOI":"10.1021\/acsnano.5c09413","article-title":"Spatiotemporally controlled nanomicelles for synergistic phototherapy and immune reprogramming in triple-negative breast cancer","volume":"19","author":"Chang","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2026.218690_bib348","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1186\/s12951-025-03708-0","article-title":"Astragalus polysaccharide-based nano-platforms loading PTX to boost chemo-immunotherapy for triple-negative breast cancer with intrinsic GLUT-targeting ability and immunoregulatory activity","volume":"23","author":"Lan","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.canlet.2026.218690_bib345","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41571-020-0410-2","article-title":"Clinical development and potential of photothermal and photodynamic therapies for cancer","volume":"17","author":"Li","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218690_bib349","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s43556-025-00306-2","article-title":"Single-cell RNA sequencing identifies CD8Teff cell activation as a predictive biomarker in triple-negative breast cancer immunotherapy","volume":"6","author":"Mao","year":"2025","journal-title":"Mol Biomed"},{"key":"10.1016\/j.canlet.2026.218690_bib350","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1111\/jcmm.16791","article-title":"CELF2 is a candidate prognostic and immunotherapy biomarker in triple-negative breast cancer and lung squamous cell carcinoma: a pan-cancer analysis","volume":"25","author":"Wang","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.canlet.2026.218690_bib351","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41523-025-00828-6","article-title":"Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer","volume":"11","author":"Balko","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib360","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010365","article-title":"Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer","volume":"13","author":"Chen","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib352","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10549-024-07426-3","article-title":"Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer","volume":"208","author":"Foldi","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2026.218690_bib353","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.medj.2023.04.008","article-title":"CCL19(+) dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer","volume":"4","author":"Wu","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.canlet.2026.218690_bib354","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41523-021-00287-9","article-title":"Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study","volume":"7","author":"Barroso-Sousa","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib355","article-title":"Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218690_bib356","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000764","article-title":"Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4","volume":"8","author":"Marshall","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218690_bib357","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102964","article-title":"The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab","volume":"9","author":"Buisseret","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.canlet.2026.218690_bib358","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113530","article-title":"OSU-T315 overcomes immunosuppression in triple-negative breast cancer by targeting the ILK\/NF-kappaB signaling pathway to enhance immunotherapeutic efficacy","volume":"143","author":"Wang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2026.218690_bib359","article-title":"Deciphering immune predictors of immunotherapy response: a multiomics approach at the pan-cancer level","volume":"6","author":"Li","year":"2025","journal-title":"Cell Rep. Med."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:45:19Z","timestamp":1788482719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526004544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":361,"alternative-id":["S0304383526004544"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218690","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy resistance in triple-negative breast cancer: Mechanisms and emerging therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218690"}}